Immunic, Inc.
IMUX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $20 | $21 | $22 | $22 |
| G&A Expenses | $0 | $6 | $5 | $0 |
| SG&A Expenses | $6 | $6 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26 | $27 | $27 | $26 |
| Operating Income | -$26 | -$27 | -$27 | -$26 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $1 | $0 |
| Pre-Tax Income | -$26 | -$27 | -$25 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26 | -$27 | -$25 | -$25 |
| % Margin | – | – | – | – |
| EPS | -0.13 | -0.2 | -0.25 | -0.28 |
| % Growth | 35% | 20% | 10.7% | – |
| EPS Diluted | -0.13 | -0.2 | -0.25 | -0.28 |
| Weighted Avg Shares Out | 194 | 132 | 101 | 90 |
| Weighted Avg Shares Out Dil | 194 | 132 | 101 | 90 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$26 | -$27 | -$27 | -$25 |
| % Margin | – | – | – | – |